Abstract
In healthy volunteers the emetic effect of apomorphine (5–10 mg, i.m.) was prevented by haloperidol (2 mg), metoclopramide (10 mg) and sulpiride (100 mg), injected intramuscularly. In parkinsonian patients, apomorphine (1 mg) given alone ameliorated the neurological symptoms (30% improvement in the disability score), but the improvement was accompanied by nausea, vomiting, sedation or sleepiness. Haloperidol (2 mg) prevented not only the emetic effect of apomorphine (10 mg), but also its therapeutic efficacy in parkinsonism. Indeed, the disability score was worsened by the drug combination in some patients. Moreover, after haloperidol, apomorphine produced deep sedation and sleep. By contrast, in parkinsonian patients pretreated with metoclopramide (10 mg) or sulpiride (100 mg), apomorphine (10 mg) markedly diminished tremor and rigidity and failed to produce nausea, vomiting and sleepiness.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Borenstein, P., Cujo, Ph., Champion, C., Olivenstein, C.: Etude d'un nouveau psychotrope: le sulpiride (1403 RD). II. Etude clinique et électroencéphalographique. Ann. médico-psychol.126, 100 (1968)
Borison, H. L., Wang, S. C.: Locus of the central emetic action of cardiac glycosides. Proc. Soc. exp. Biol. (N.Y.)76, 335 (1951)
Braham, I., Sarova Pinhas, I., Goldhammer, Y.: Apomorphine in parkinsonian tremor. Brit. med. J.1970 III, 768.
Bunney, B. S., Aghanjanian, G. K.: Evidence for drug actions on both pre- and postsynaptic catecholamine receptors in the CNS. In: Pre- and postsynaptic receptors, E. Usdin and W. E. Bunney, Jr., eds., pp. 89–122. New York: Marcel Dekker 1975
Castaigne, P., Laplane, D., Dordain, G.: Clinical experimentation with apomorphine in Parkinson's disease. Res. Comm. Chem. Path. Pharmacol.2, 154–158 (1971)
Cornet, A., Grivaux, M., Guerre, J.: Dyskinésies et troubles fonctionnels digestifs traités par le métoclopramide. Sem. Hôp. Paris40, 2346–2350 (1964)
Cotzias, G. C., Papavasiliou, P. S., Fehling, C., et al.: Similarities between neurologic effects of levodopa and of apomorphine. New Engl. J. Med.282, 31–33 (1970)
Duby, S. E., Cotzias, G. C., Papavasiliou, P. S., Lawrence, W. H.: Injected apomorphine and orally administered levodopa in Parkinsonism. Arch. Neurol. (Chic.)27, 474–480 (1972)
Ernst, A. M.: Mode of action of apomorphine and dex-amphetamine on gnawing compulsion in rats. Psychopharmacologia (Berl.)10, 316 (1967)
Farnebo, L., Hamberger, B.: Drug-induced changes in the release of3H-monoamines from field stimulated rat brain slices. Acta physiol. scand., Suppl. 371, 35–44 (1971)
Janssen, P. A. J., Niemegeers, C. J. E., Schellekens, K. H. L., Dresse, A. D., Lenaerts, F. M., Pinchard, A., Schaper, W. K. A., Van Neuten, J. M., Verbruggen, F. J.: Pimozide, a chemically novel, highly and orally long acting neuroleptic drug. 1. The comparative pharmacology of pimozide, haloperidol and chlorpromazine. Arzneimittel-Forsch. (Drug Res.)18, 261 (1968)
Justin-Besancon, L., Laville, Cl.: Action antémétique du métoclopramide vis-à-vis de l'apomorphine et de l'hydergine. C.R. Soc. Biol. (Paris)158, 723–727 (1964)
Kehr, W., Carlsson, A., Lindquist, M., Magnusson, T., Atack, C.: Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J. Pharm. Pharmacol.24, 744–747 (1972)
Laville, Cl.: Effets du métoclopramide sur le système nerveux central (tests de la tige tournante et de la traction chez la souris, tests de la catalepsie chez le rat). Path. et Biol.12, 723–725 (1964)
Laville, Cl., Margarit, J.: Sur les effets neurologiques centraux du sulpiride. Path. Biol.17, 71 (1969)
Laville, Cl., Margarit, J.: Activité anti-émétique du sulpiride vis-à-vis des divers poisons émétisants chez le chien. C.R. Soc. Biol. (Paris)162, 869 (1968)
Rotrosen, J., Wallach, M., Angrist, B., Gershon, S.: Antagonism of apomorphine-induced stereotypy and emesis in dogs by thioridazine, haloperidol, and pimozide. Psychopharmacologia (Berl.)26, 185–194 (1972)
Schwab, R. S., Amador, L. V., Lettvin, J. Y.: Apomorphine in Parkinson's disease. Trans. Amer. Neurol. Ass.76, 251–253 (1951)
Snedecor, G. W., Cochran, W. G.: Statistical methods. In: Statistical methods. Sixth edition, G. W. Snedecor and W. G. Cochran, eds. Ames, Iowa: Iowa State University Press 1972
Tagliamonte, A., DeMontis, G., Olianas, M., Vargiu, L., Corsini, G. U., Gessa, G. L.: Selective increase of brain dopamine synthesis by sulpiride. J. Neurochem.24, 707–710 (1975)
Ungerstedt, V.: Poystsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta physiol. scand., Suppl. 367, 69–93 (1971)
Wang, S. C.: Emetic and anti-emetic drugs. In: Physiological pharmacology, Vol. 2, W. S. Root and F. G. Hofman, eds., pp 255–328. New York: Academic Press 1965
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Corsini, G.U., Del Zompo, M., Cianchetti, C. et al. Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in parkinsonism. Psychopharmacology 47, 169–173 (1976). https://doi.org/10.1007/BF00735817
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00735817